U.S. markets close in 2 hours 15 minutes
  • S&P 500

    3,247.09
    -63.02 (-1.90%)
     
  • Dow 30

    26,246.98
    -412.13 (-1.55%)
     
  • Nasdaq

    10,859.22
    -326.37 (-2.92%)
     
  • Russell 2000

    1,539.85
    -21.73 (-1.39%)
     
  • Crude Oil

    35.36
    -0.81 (-2.24%)
     
  • Gold

    1,879.30
    +11.30 (+0.60%)
     
  • Silver

    23.63
    +0.27 (+1.16%)
     
  • EUR/USD

    1.1646
    -0.0033 (-0.28%)
     
  • 10-Yr Bond

    0.8550
    +0.0200 (+2.40%)
     
  • GBP/USD

    1.2944
    +0.0021 (+0.16%)
     
  • USD/JPY

    104.6300
    +0.0200 (+0.02%)
     
  • BTC-USD

    13,501.29
    +202.45 (+1.52%)
     
  • CMC Crypto 200

    263.62
    -0.02 (-0.01%)
     
  • FTSE 100

    5,577.27
    -4.48 (-0.08%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

Oppenheimer & Co. Inc. Expands Life Sciences Research Team With Addition Of Frank Brisebois As Managing Director And Senior Analyst

·2 mins read

NEW YORK, June 3, 2020 /PRNewswire/ -- Oppenheimer & Co. Inc. ("Oppenheimer") – a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) – today announced the expansion of its Life Sciences research team with the addition of Frank Brisebois as Managing Director and Senior Analyst. The appointment of Mr. Brisebois to this position, covering Biotechnology and Biopharmaceuticals, reflects Oppenheimer's ongoing commitment to developing best-in-class analysis and research related to the Life Sciences sector.

"These are dynamic times in the Life Sciences sector, with new therapies and technological innovations poised to revolutionize entire business models," said John Parks, Managing Director & Director of Equity Research at Oppenheimer. "The Life Sciences sector has historically been a strong area of focus for Oppenheimer. Frank's experience and insights will reinforce our Life Sciences expertise during a time of significant change, while expanding our research offerings in ways that strengthen and grow our Life Sciences team."

With over a decade of relevant experience, Mr. Brisebois is based in Boston, and is focused on the subsectors of Ophthalmology, Audiology, Pain/CNS, Cannabis Derivatives, and Digital Medicine. Prior to joining Oppenheimer, he was a Senior Research Analyst at Craig-Hallum Capital covering Biotechnology and Biopharmaceuticals. He also previously worked at Laidlaw Capital Markets for five years and started his career at healthcare specialty firm Summer Street Research Partners. He holds a Bachelor of Arts in Molecular Biology from Colgate University, and a Master of Science in Pharmaceutical Sciences from the University of Montreal.

Mr. Brisebois said, "I'm excited to join Oppenheimer's Life Sciences research team, which has distinguished itself over the years with its strong insights and analysis about this sector. I look forward to partnering closely with my new colleagues to continue to strengthen the firm's longstanding expertise in Life Sciences."

Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc. Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), and its affiliates provide a full range of wealth management, securities brokerage and investment banking services to high net-worth individuals, families, corporate executives, local governments, businesses and institutions.

Media Contact:
Joseph Kuo / Michael Dugan
Haven Tower Group LLC
424 317 4851 or 424 317 4852
jkuo@haventower.com or mdugan@haventower.com

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/oppenheimer--co-inc-expands-life-sciences-research-team-with-addition-of-frank-brisebois-as-managing-director-and-senior-analyst-301069746.html

SOURCE Oppenheimer & Co. Inc.